VSTM · Verastem, Inc.

The thesis

Verastem's shares turn on the 14 October 2026 first efficacy readout for VS-7375, its oral KRAS G12D cancer drug. Underneath sits an ovarian-cancer launch that brought in $25.1 million of net product revenue in the June quarter. Tumor response rates in pancreatic and lung cancer will decide whether the pipeline adds value on top of that business.

Revolution Medicines set the bar. On 2 July 2026 it reported a 50% objective response rate (ORR) for its zoldonrasib plus daraxonrasib combination in 30 second-line pancreatic cancer patients. VS-7375 will be shown mostly as a single drug in early-stage groups. Groups that small cannot rank the drugs. Investors will still set the figures side by side on the day. Revolution Medicines release, 2 July 2026

The narrative is maturing but warming into the event: the date has been public since 8 September 2026, and the shares closed at $8.11 on 8 October 2026, above the $7.70 to $8.02 range of tracked closes from September into early October. The move came with no new company release; BTIG's 8 October 2026 reiteration of its Buy rating and $18 target was the only company-specific news that day. A weekly close below $6.70 after the event would show the market rejecting the data.

Bullish and bearish views on Verastem, Inc.

The bull case on Verastem, Inc. (VSTM), in brief: Launch revenue funds the pipeline. The bear case: The comparison bar is high.

Bull case

• Launch revenue funds the pipeline. Verastem reported $25.1 million of AVMAPKI FAKZYNJA CO-PACK net product revenue for the quarter ended 30 June 2026. Q2 results, 6 August 2026
• Financing so far avoided share issuance. The Oberland Capital royalty deal provides up to $75 million, with the first $50 million received at closing on 28 August 2026. A further $25 million is optional if quarterly CO-PACK sales reach $40 million by the first quarter of 2027.
• New ovarian data support the approved drug. An external control-arm analysis at the International Gynecologic Cancer Society meeting, announced 2 October 2026, showed a weighted ORR of 38.7% for the CO-PACK combination against 0% for conventional care in KRAS-mutated low-grade serous ovarian cancer. Weighted median progression-free survival was 22.1 months against 6.5 months.
• The program has scale and regulatory backing. The Q2 release reported more than 200 patients treated with VS-7375, a cleared 1,200 mg daily dose with no dose-limiting toxicities, and first patients dosed in all three registration-directed TARGET-D Phase 2 trials. The FDA granted Fast Track designation in KRAS G12D-mutated lung cancer on 3 June 2026, adding to an earlier pancreatic designation. Business Wire, 3 June 2026
• Analyst support held into the event. BTIG reiterated Buy with an $18 target on 5 October 2026 and again on 8 October 2026; H.C. Wainwright did the same on 5 October 2026. Wolfe Research initiated at Outperform on 17 September 2026. StockAnalysis.com listed an average target of $14.67 across 10 analysts on 5 October 2026, with a range of $11 to $18.

Bear case

• The comparison bar is high. Revolution Medicines' 50% second-line pancreatic ORR from 2 July 2026 came from a two-drug regimen. A single-drug VS-7375 pancreatic rate well below that figure would likely be read as second-tier.
• The field is crowded and moving earlier. Incyte's 10-Q for the quarter ended 30 June 2026 reports that its Phase 3 DAWN-303 trial of KRAS G12D inhibitor INCB161734 with chemotherapy in first-line pancreatic cancer began in the first quarter of 2026. Rivals in front-line trials narrow the room for a later-line entrant. Incyte 10-Q
• The shares ran into the event. The 8 October 2026 close of $8.11 is 51.0% above the level of three months earlier, and the 14-day relative strength index stood at 59.7. A run-up before a binary readout raises the chance of a drop on mixed data.
• The cash runway is finite. Pluto Analyses put the Q2 2026 net loss at about $40 million on 5 October 2026, against $136.4 million of cash at 30 June 2026. Three registration-directed trials raise spending; a share sale after the readout would dilute holders.

Price setup

The last close was $8.11 on 8 October 2026, according to adjusted daily closes. That is 23.8% below the 52-week high of $10.64 and 51.0% above the close three months earlier. The relative strength index (RSI, 14-day) was 59.7, elevated but short of overbought.

The 8 October 2026 close cleared the $7.70 (2 October 2026) to $8.02 (2 September 2026) range of tracked closes since early September. Every September close sat above $6.70; the lowest tracked was $7.74 on 25 September 2026. A weekly close below $6.70 would put the shares under that whole pre-event range. A close back above $10.64, the 52-week high, would show the market pricing the data as competitive.

Catalysts, next 30 days

• 14 October 2026, 8:00 am ET: VS-7375 investor event with first efficacy and updated safety data in pancreatic, lung and colorectal cancers from the TARGET-D program, with oncologist Manuel Hidalgo Medina joining management. Verastem release, 8 September 2026
• ~5 November 2026, est.: Q3 2026 results; the company has not confirmed the date. It tests whether CO-PACK revenue grows past $25.1 million a quarter toward the $40 million level that unlocks the optional $25 million Oberland tranche.

What would change the view

The case breaks if the 14 October 2026 event is postponed or reports no tumor response rates. It also weakens if the pancreatic response rate reads well below Revolution Medicines' 50% and analysts cut targets toward the $11 low end of the range. On price, a weekly close below $6.70 ends the thesis.

On the business side, Q3 CO-PACK revenue at or below $25.1 million would show the launch stalling. A share sale soon after the readout, or a RAMP 301 confirmatory-trial miss, would undercut the funding and the approved franchise beneath the pipeline.

What it trades with

The shares trade on company-specific clinical news first. KRAS G12D readouts from Revolution Medicines and Incyte move the read on VS-7375 directly, so their data releases act as indirect catalysts. As a small-cap biotech, Verastem also tends to track small-cap biotech indexes on days without company news.